AxoGen, Inc. (NASDAQ:AXGN) Short Interest Update

by · The Markets Daily

AxoGen, Inc. (NASDAQ:AXGN – Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 1,010,000 shares, a decrease of 7.3% from the November 30th total of 1,090,000 shares. Based on an average daily trading volume, of 356,700 shares, the short-interest ratio is presently 2.8 days.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

View Our Latest Stock Report on AxoGen

AxoGen Stock Down 0.1 %

AXGN stock traded down $0.01 during trading on Wednesday, hitting $16.48. 589,798 shares of the company’s stock were exchanged, compared to its average volume of 392,300. The business has a 50-day moving average price of $14.32 and a two-hundred day moving average price of $12.23. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $725.25 million, a price-to-earnings ratio of -51.50 and a beta of 1.06. AxoGen has a 52-week low of $5.55 and a 52-week high of $17.23.

Institutional Trading of AxoGen

Several institutional investors have recently modified their holdings of AXGN. Sentry Investment Management LLC grew its stake in AxoGen by 9.3% during the 3rd quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock worth $243,000 after buying an additional 1,483 shares during the last quarter. Quest Partners LLC increased its holdings in shares of AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 2,076 shares during the period. Rhumbline Advisers increased its holdings in shares of AxoGen by 6.2% in the 2nd quarter. Rhumbline Advisers now owns 58,157 shares of the medical equipment provider’s stock valued at $421,000 after acquiring an additional 3,380 shares during the period. nVerses Capital LLC purchased a new stake in AxoGen in the 3rd quarter valued at $56,000. Finally, Franklin Resources Inc. grew its position in AxoGen by 9.8% during the 3rd quarter. Franklin Resources Inc. now owns 76,048 shares of the medical equipment provider’s stock worth $1,084,000 after purchasing an additional 6,767 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

About AxoGen

(Get Free Report)

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

See Also